Skip to content

Viking Therapeutics

US · VKTX #2352 by market cap Listed 2015
24.77 -1.07 -4.14%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:56

Price chart

Pre-market 25.57 -1.04%
After-hours 25.10 +1.33%
Overnight 25.65 -0.74%
42.1324.2124.772026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on VKTX?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is -27.8% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has fallen to 18.9% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days D → E

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-21 20:27 UTC

Data coverage: 4 of 6 factors. Missing data is not a zero score.

Overall C

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability D-

How much profit the business keeps from each dollar of sales and capital.

Return on equity -47.3% Better than 9%
Return on invested capital -51.7% Better than 6%
Momentum D+

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -26.9% Better than 21%
6-month return -19.8% Better than 27%
12-month return (ex latest month) -24.6% Better than 12%
Distance below 52-week high 42.5% Better than 26%
Financial Health A-

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 9.3x Better than 93%
Debt to assets 0.0% Better than 99%
Interest coverage -53.6x Better than 7%
Analyst View A+

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 93.8% Better than 76%
Upside to average target 277.6% Better than 97%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -15.23%
1M -7.26%
3M -27.91%
6M -15.86%
YTD -29.59%
1Y -27.72%
3Y +110.45%
5Y +339.18%

Key statistics

Price & volume

Prev close
25.84
Open
25.62
Day range
24.67 - 26.50
Avg price
25.17
Volume
3.65M
Turnover
91.98M
Amplitude
7.08%
52-week range
23.82 - 43.10

Valuation

P/E
-7.76
P/E (TTM)
-4.57
P/B
5.37
EPS
-3.19
Net profit
-406.80M
Net assets
588.64M

Share structure

Market cap
3.16B
Float cap
3.09B
Shares out
127.52M
Float shares
124.60M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2015-04-29
52-week range 5% of range
23.82 43.10

42.5% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-22.91M net over the window

Short interest

Shares short
24.16M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Viking Therapeutics (VKTX)?

Viking Therapeutics last traded at 24.77. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Viking Therapeutics's market cap?

About 3.16B.

What is the P/E ratio of Viking Therapeutics?

The trailing twelve-month P/E is -4.57. The Valuation tab shows it against the stock's own five-year range.

Does Viking Therapeutics pay a dividend?

Viking Therapeutics does not currently pay a regular dividend.

Is Viking Therapeutics a buy according to analysts?

The consensus of 16 analysts is a Buy rating, with an average 12-month price target of 93.53, which implies 277.6% upside from the current price. This is not investment advice.

What is Viking Therapeutics's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Viking Therapeutics a E (Strong Sell). Below its 200-day average and near the bottom of the universe on momentum. Not investment advice.

Quote time 2026-11-20 19:56:05 · For reference only, not investment advice and not tailored to your situation.

Viking Therapeutics discussion 0 comments

Add a comment